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1. Introduction 
Gene therapy is often referred to as transfer of transgenes into the somatic cells of a patient 
to obtain a therapeutic effect .One of the goals for all such therapies is efficient and safe 
delivery of the desired extrinsic genes into target cells, thereby increasing the therapeutic 
efficiency (Robson & Hirst, 2003). This has been a major obstacle in gene therapy 
experiments (Sarbolouki et al., 2000;  Sadeghizadeh et al., 2008). 
To address this problem, there has been an increasing number of reports in the development 
of efficient gene delivery vehicles in recent years (Sadeghizadeh et al., 2008). Clinical trials 
have also focused on the delivery of genes directly to the target area e.g. tumor sites by 
intratumoral administration of both viral and non-viral delivery agents. But the problem 
remains to be overcome yet, as majority of tumors are not accessible for direct injection. A 
number of strategies are now being developed to target viral and non-viral delivery agents 
to tumor sites. These include genetically modifying viral carriers and incorporating a novel 
tumor-specific ligand into the viral coat proteins to direct the viral system to a tissue 
receptor and also incorporation of tissue specific ligands and monoclonal antibodies onto 
the surface of non-viral carriers (Robson & Hirst, 2003). The delivery of the carrier system to 
the target site is however not the end of the goal. Efficient entrance of the gene or drug into 
the cells and expression of therapeutic gene are also the next hurdles to be overcome. There 
are several techniques for delivery of genes as well as drugs into eukaryotic cells using 
similar carriers practiced in-vitro and in-vivo. The in-vivo efficacy of a gene or drug delivery 
system depends on its capability to pass the main extracellular and intracellular barriers 
encountered from the site of administration to entry into the nucleus of desired cells 
(Sarbolouki et al., 2000;  Sadeghizadeh et al., 2008). 
The therapeutic effect of a gene therapy experiment would be expected once the introduced 
transgene in target cells is considered as part of the genetic component of host cell and leads 
to the production of a new functional protein. To date, this type of gene transfer known as 
transfection   (Lewin, 2007; Singleton & Sainsbury, 1995) has been studied widely and 
various techniques have been developed for it, each possessing its own advantages and 
shortcomings. Generally speaking, gene delivery techniques are classified into viral and 
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non-viral categories. Non-viral systems include physical, chemical and biological methods. 
Conventional physical techniques include electroporation and microinjection. Among 
chemical methods are calcium-phosphate precipitation, use of diethylaminoethyl (DEAE), 
polyethylenimines (PEIs), polybrene/dimethyl sulfoxide, liposomes, cationic amino 
polymers, polyamidoamin (PAMAM), dendrimers and dendrosomes (Guyden, 1993; 
Hammarskjold, 1991). Biological methods embrace viral transfer systems which utilize 
SV40-based vectors, adenoviral vectors, vaccina virus vectors, BPV vectors and retroviral 
carriers (Hammarskjold, 1991; Wong & Neuman, 1982) and non-viral systems which  
bacteriophages are among the most important. A detailed description all of these delivery 
systems lies beyond the scope of this paper (for review see references Hammarskjold, 1991; 
Wong & Neuman, 1982). 
Nanotechnology referred to as the creation of useful materials, devices and systems used to 
manipulate matter at an extremely small size -between 1 and 100 nm- (Alivisatos, 1996;  
Suntherland, 2002) offers great opportunity in the field of drug and gene delivery. The 
problems and shortcomings of current anti-cancer treatment strategies such as systemic 
administration of drugs or genes which do not greatly differentiate between cancerous and 
normal cells leading to systemic toxicity and adverse effects, have caused limitations in 
allowable dose of drugs (Sinha et al., 2006) and led to a resurgence of interest in developing 
safe and efficient nano-scale gene and drug porters capable of detecting target sites and 
delivering proper genes and/or drugs to diseased cells (Sadeghizadeh et al., 2008). 
In recent years, a number of nanoparticle-based therapeutic agents have been developed for 
treatment of cancer, diabetes, asthma, allergy, infection, etc. (Brannon-Peppas & Balanchette, 
2004; Kawasaki & Player, 2005) . These nano-scale agents may provide more efficient and/or 
more convenient routes of administration, have lower toxicity, extend the product life-cycle 
and ultimately allow targeted and controlled release of therapeutic gene or drug (Zhang et 
al., 2007). 
It has previously been reported that dendrosomes are capable of easily delivering genes into 
human cells (e.g. human hepatocytes, kidney cells and several cancer cell lines) and animal 
models in-vivo. They are easily synthesized, highly stable (nearly 4 years at ambient 
conditions) and extremely convenient to handle and use (Sarbolouki et al., 2000;  
Sadeghizadeh et al., 2008). 
In this chapter, we discuss some of the most commonly used non-viral gene delivery 
systems (some also used as drug-carriers), with a focus on features of the recently 
introduced dendrosomes as novel gene porters shedding more light onto future 
perspectives of these promising nanocarriers. 
Non-viral biological gene delivery methods include bacteria, bacteriophages, virus-like 
particles (VLPs), erythrocyte ghosts and exosomes. Elaboration on all of these approaches is 
beyond the scope of this chapter. Unavoidably, in this regard we will narrow our debate to 
bacteriophages being one of our  research interests. Hence, at the end of the chapter, 
bacteriophages as one of the most significant non-viral biological systems or strategies for 
gene delivery developed over the recent years will be discussed (Seow & Wood, 2009). 
2. Chemical strategies 
2.1 Calcium-phosphate precipitation  
This technique is the most common way to transfect foreign genes into eukaryotic cells 
mainly due to its simplicity and inexpensiveness. In this technique, foreign genes are 
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precipitated on the surface of cell monolayer. Briefly, calcium  chloride, DNA and 
phosphate buffer are mixed at a neutral pH, the calcium-phosphate-DNA complex then 
precipitates on the cells and would enter the cells through endocytosis. These complexes are 
then transported to different organelles including the nucleus (Guyden, 1993). In order to 
increase the efficiency of transfection, addition of glycol/dimethyl sulfoxide to the 
monolayer following precipitation of the complex and removal of the old medium has been 
effective (Okayama et al., 1991; Li & Thacker, 1997).   However, this method suffers from 
frailties including  transient and unstable expression of tranfected genes following their 
degradation, low percentage of stably-transformed cells (only 0.001- 1%) and the need to 
determine the optimum conditions for transfectoin of each cell type. 
Nevertheless, calcium phosphate nanoparticles introduced by Roy et al. (2003)  are ultra-low 
size entities around 80 nm in diameter and it seems to be able to protect encapsulated DNA 
from environmental DNases with capability of surface modifications. This new class of 
nanoparticles have been used for gene delivery to liver. 
2.2 Diethylaminoethyl (DEAE)-dextran 
This method is based upon the negative charge of DNA and the positive charge of diethyl 
aminoethyl-dextran leading to the formation of a complex and adherence of the complex to 
the cell surface followed by endocytosis. This technique benefits from advantages such as 
simple and rapid preparation steps, low cost and reproducibility. However, cells show 
different sensitivities to the toxicity of this compound, therefore the proper ratio of 
diethylaminoethyl-dextran-DNA must be determined for each cell line (Holter et al., 1989). 
Moreover, it is preferred for transfection of adherent cells over cells in suspension (Gulick, 
2003). 
2.3 Polycations 
Many libraries perform DNA trasfection experiments using artificial polycations such as 
polybren/dimethyl sulfoxide which have been shown to enhance retroviral infection in cell 
cultures by making an electrostatic bridge between the negatively charged viral particles 
and neutral components of the recipient cell membrane. It also binds DNA and attaches it to 
the cell surface. Finally, exposing the cells to dimethyl sulfoxide  increases the speed of DNA 
uptake. It is a proper method when dealing with very limited amounts of DNA (ng DNA). 
The efficiency of this technique is sometimes 0.01-0.1% (Roy et al., 2003). Other polycation-
based systems may also utilize poly-lysine compounds (Sarbolouki et al., 2000). Of the most 
widely used gene carriers of this category are polyethylenimines (PEIs). Linear or branched 
PEIs have been efficiently used for in vitro transfection of genes. However, in vivo 
application of PEIs, leads to non-specific interactions of the PEI/DNA complex with 
components of the host blood and results in failure of proper gene delivery. Thus, various 
surface modified derivatives of PEIs (polyethylene glycol-conjugated PEIs) have been 
emerging to overcome these issues (Kichler, 2004). 
2.4 Polymeric L-lysin vehicles 
Poly L-lysin, also referred to as PLL, has been shown to form complexes with DNA as a 
result of interaction of negatively charged DNA and positively charged amino groups of 
lysine (Tae et al., 2006). These polyelectrolyte complexes have also been shown to suffer 
from drawbacks e.g. high degree of cytotoxicity, rapid clearance and self aggregation (Liu et 
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al., 2001). Similar to that of PEIs, surface conjugation of PLL with polyethylene glycol, has 
been shown to improve properties of this class of gene delivery vehicles. In addition, 
various strategies have been employed to target PLL polymers to specific cell types or 
tissues. These include conjugating sugar moieties e.g. lactose or galactose to target 
PPL/DNA complexes to hepatocytes (Nishikawa et al., 1998; Hashida et al., 1998). There 
have also been efforts to conjugate antibodies (e.g. leukemia-specific- antigen antibody, anti 
JL-1 antibody) to PLL complexes showing higher leukemia-specific cell uptake and 
specificity (Suh et al., 2001). 
2.5 Polysaccharides as gene carriers 
There are known examples of using polymers composed of sugar molecules, e.g. chitosan 
and cyclodextrin, for gene delivery purposes. Cyclodextrin is in fact a cyclic entity made up 
of oligomeric glucose units forming a hydrophobic internal cavity and a hydrophilic 
extremity. Another example is chitosan, a polysaccharide made up of repetitive units of D-
glucosamine linked to N-acetyl-D-glucosamine. Both above mentioned polysaccharide-
based structures can interact with DNA to form stable complexes and have been reported to 
have comparable or higher transfection efficiencies in regard to PEI or PLL (Gonzalez et al., 
1999).  
3. Liposome-based gene/drug delivery systems 
Liposomes are spherical lipid vesicles with bilayer membrane structure composed of natural 
or synthetic amphiphilic lipid molecules (Zhang & Granick, 2006). Liposomes have been 
widely used as pharmaceutical carriers in the past decade because of their unique abilities in 
encapsulating both hydrophilic and hydrophobic agents with a high efficiency, protecting 
the encapsulated drugs from undesirable side effects of external conditions, being 
functionalized with specific ligands that can target specific cells, and being coated with inert 
biocompatible polymers (Roy et al., 2003; Moghimi & Szebeni, 2003). Liposomes are also 
used as gene carriers. An efficient strategy to encapsulate DNA within liposome is the 
reverse phase evaporation method (REV) in which phospholipids are resolved in ether 
making up an organic phase and DNA is added to PBS making up an aqueous phase. Then 
the aqueous and the organic phases are emulsified in a sonicator followed by mixing the 
lipids with DNA which leads to the formation of lipid vesicles containing the DNA 
molecules inside (Guyden, 1993). Since liposomes are usually not fused to the cell surface 
but rather phagocytosized by cells, the carried nucleotides would be exposed to the 
lysosomic enzymes and therefore digested, reducing the efficiency of successful 
transfection/expression process. Other problems of liposomes include the possibility of 
formation of small-sized liposomes uncapable of encapsulating large macromolecules such 
as DNA and the multistep difficult processes of their production. They also have a low gene 
transfer efficiency and usually exhibit cytotoxicity in lymphoma cells (Buttgereit et al., 2000). 
3.1 Cationic liposomes 
Cationic liposomes such as lipofectins have also been developed to overcome some of 
mentioned  shortcomings of liposomes. Lipofectins contain positively charged lipids like  
dioleoylphosphatidylethanolamine (DOPE) and N-(1-2,3-dioleyloxypropyl)-N,N,N-
trimethylammonium (DOTMA). DOTMA for example, is designed as stable cationic bilayer 
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vesicles spontaneously interacting with polyanionic DNA and RNA molecules and therefore 
forming liposome/polynucleotide complexes. These complexes are taken in by the anionic 
surface of host cells with an efficiency of about 10-100 fold higher than that of negatively or 
neutrally charged liposomes. Large DNA molecules such as baculoviral DNA (130 kb) and 
genomes of RNA-viruses have also been introduced into cell-cultures using DOTMA 
confirmed by the formation of viral particles (Felgner, 1991; Strauss et al., 1994). 
3.2 Modified and targeted liposomes 
One drawback of the use of liposomes is the fast clearance of liposomes from blood by 
phagocytic cells of the reticuloendothelial system, resulting in unfavorable therapeutic index 
(Roy et al., 2003). One of the widely used strategies is to formulate long-circulating 
liposomes by coating the liposome surface with inert biodegradable polymers such as 
polyethylene glycol. The polymer layer provides a protective shell over the liposome surface 
and suppresses liposome recognition by opsonins and therefore subsequent clearance by the 
reticuloendothelial system (Dutta et al., 2006). Another strategy is to increase the 
accumulation of liposomes in the target site by attaching targeting ligands such as 
antibodies and small moiety molecules (e.g. folate and transferrin) to the liposome surface. 
Targeted liposomes have been developed for differential drug and gene delivery (Saunak et 
al., 2004).  
4. Nanopolymer-based carriers 
4.1 Dendrimers 
Dendrimers are a class of artificial, highly branched and reactive three dimensional 
polymers, with all bonds originating from a central core. The term dendrimer comes from 
the Greek word “dendron” which means tree and the suffix “mer” from meros referring to 
smallest repeating units. In recent years, there has been much interest in dendrimers; since 
due to the large number of terminal functional groups (e.g. amino groups) on their surface, 
they are easily linkable to antibodies and reactive therapeutic agents making them proper 
for use in biomedical research (Bousif et al., 1995; Buttgereit et al., 2001; Massumi et al., 
2005). Other attractive features such as nanoscale size, highly controllable molecular weight 
and possibility of encapsulating a guest molecule (e.g. a gene or drug) in their internal 
cavities (Tomalia, 2005) give dendrimers a distinctive advantage over other polymers for 
delivery of drugs and genes (Strauss, 1994). To use DNA therapeutically, it must pass some 
barriers in the body of host, including capillary endothelial cells, phagocytes, 
reticuloendothelial system and eventually the membrane of the target cell (Dutta et al., 
2006). The nanoscopic size of dendrimers not only helps them evade the reticuloendothelial 
system, but also generates benefit for them in intracellular delivery [34]. Amino-dendrimers 
have been specifically attractive due to their defined structures and the large number of 
surface amino groups ((Sarbolouki et al., 2000;  Sadeghizadeh et al., 2008; Bielinska et al., 
1997). Ployamidoamin (PAMAMs) dendrimers are a member of this family of dendrimers 
known as water soluble constructs covered with a large number of amino groups on their 
surface due to which they are positively charged at physiologic pH and therefore thought to 
interact with DNA (Sadeghizadeh et al., 2008; Kukowska et al., 1996) . Another member of 
this family “poly (propyleneimine) dendrimers” (PPI) are also highly branched and globular 
with primary amino groups on the periphery (Saunak, 2004). As a result, these dendrimers 
readily form complexes with DNA and are capable of transfecting cell cultures with low 
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toxicity and higher efficiency. Dendrimers have different generations and modification of 
the large number of surface functional groups by conjugation to guest molecules has led to 
the production of dendrimer conjugates (Buttgereit et al., 2001; Massumi et al., 2005). For 
example, in a recent study, labeled biotin-conjugated PAMAM dendrimers were constructed 
and used to target tumor cells. As biotin specific receptors are overexpressed on the surface 
of cancer cells, results have shown an increased carrier uptake by these cells (Pourasgari et 
al., 2007). 
There are few studies on the antigenic properties of nanoparticles such as dendrimers. An 
early study on PAMAM dendrimers did not reveal overt antigenicity of generations 3, 5 and 
7 amino-terminated dendrimers (Dutta et al., 2006). In a study on immunosuppressive 
properties of dendrimers, generations 3 and 5 PAMAM dendrimers conjugated to 
glucosamine strongly inhibited induction of inflammatory cytokines and chemokines in 
human macrophages and dendritic cells exposed to bacterial endotoxins. Also, dendrimers 
have been reported to possess hemolytic toxicity and cytotoxicity owing to their cationic 
nature. Moreover, interaction with oppositely charged macromolecules in plasma may 
result in premature release of their cargo (e.g. plasmid DNA or carried drug) within the 
blood (Buttgereit et al., 2001). In addition, degradation of the plasmid DNA by plasma 
DNases leads to poor gene expression in-vivo (Massumi et al., 2005; Pourasgari et al., 2007). 
4.2 Dendrosomes: New generation of nanoscale gene porters 
Dendrosomes, are a novel family of non-viral vehicles and gene porters that form 
hyperbranched spherical entities hence the term derndrosome is applied to them 
(Sarbolouki et al., 2000;  Sadeghizadeh et al., 2008). 
Dendrimers could be presumably considered as the primary ancestors of these novel gene 
delivery systems. Dendrosomes possess valuable advantages over other  carriers which 
include ease of synthesis, stability (nearly 4 years at ambient conditions), nontoxicity, 
inexpensiveness, biodegradability, neutrality, spherical structure, capability of easily 
delivering genes and being extremely convenient to handle and use (Sarbolouki et al., 2000;  
Sadeghizadeh et al., 2008; Dobrovolskaia & McNeil., 2007). 
According to atomic force microscopy (AFM) observations, dendrosomes are expectedly 
nanoscopic particles 10-100 nm in size .  A unique feature of dendrosomes is the ease with 
which they provide suitable inert gene porters for various DNA sizes and target cells. There 
have been several reports by our group and other researchers all showing that dendrosomes 
may serve as promising high efficient candidates for transfection and therapy (Sarbolouki et 
al., 2000;  Sadeghizadeh et al., 2008). In early studies, three generations of dendrosomes named 
Den450, 700 and 123 were synthesized and used and their applicability and efficiency were 
assessed by studies on transfection of human cell cultures as well as vaccination of mice 
against hepatitis B. To assess their cytotoxicity, cells were treated with void dendrosomes. 
These experiments showed that bare dendrosomes Den450 and Den700 when exposed to A7r5 
cells (rat aortic somatic muscle cells) not only showed no deleterious effects, but even seemed 
to help their propagation. This surprising effect probably implies the fact that these agents can 
act as adjuvants and improve uptake of nutrients by cells. Southern blot analysis also clearly 
demonstrated the episomal presence of the carried gene in the cytoplasm of transfected cells 
and therefore the capability of dendrosmes in delivery of genes into cells (Sarbolouki et al., 
2000). Several advantages of dendrosomes confer them other potentials for use in DNA 
vaccination. These include  protection of plasmid DNA from nuclease degradation, efficient 
delivery of their contents to antigen presenting cells (APCs) and extended release of cargo.  
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Mixing the HBsAg gene-harboring plasmid with a small amount of dendrosomes 
followed by intramuscular or intradermal administration of the mixture into BALB/c 
mice, resulted in a much higher production of anti-HBs antibodies compared to the 
administration of recombinant antigen itself (Sarbolouki et al., 2000). More recent studies 
by another group on the protective efficiency of dendrosomes as novel nano-sized 
adjuvants, have also approved their capability for DNA vaccination against allergy (Dutta 
et al., 2006). Conventional immunotherapies suffer from the drawbacks of use of an active 
antigen, such as sever IgE-mediated side effects like anaphylactic reactions induced by 
cross-linking of pre-existing IgE antibodies on the surface of mast cells (Buttgereit et al., 
2001). However, use of Den123 for delivery of allergen-encoding plasmid for DNA 
vaccination, yielded promising results as these nanoparticles showed IgE inhibition while 
maintaining Th1/Th2 balance after DNA vaccination, sustained release of DNA plasmids 
and augmentation of the IgG2a level gradually by prolongation of the intracellular 
presence of the plasmid (Dutta et al., 2006;  Balenga et al., 2006). In another study, the 
dendrosome Den123 was used to deliver and enhance transfection of DNA vaccine 
plasmid encoding gB gene of Herpes Simplex Virus type-1 along with Bax-encoding 
plasmid in order to evaluate the apoptosis induction effect on DNA vaccination efficiency 
(Pourasgari et al., 2007). Another group has recently synthesized and used dendrosomes 
containing entrapped PPI dendrimer-DNA complexes in genetic immunization against 
hepatitis B as well. The dendrosome formulation chosen for this study was DF3 as it 
possessed optimum size and entrapment efficiency. Animals immunized with PPI 
dendrimer-DNA complex entrapped within DF3 dendrosomes underwent maximum 
immune response in terms of total IgG compared to those immunized with plasmid DNA 
alone and/or PPI dendrimer-DNA complex. Higher level of IFN-γ in DF3-immunized 
animals also suggested that the immune response was strictly Th1-mediated (Dutta et al., 
2006). These results are in accordance with our observations about the superiority of 
dendrosomes in genetic immunization and DNA vaccination compared to other 
strategies. The dendrosomes DF3 prepared by the reverse phase evaporation method have 
also been used in transfection of HEK-293 cells with PGL2 showing that they possess a 
superior transfection against other non-viral delivery systems under study . 
In a comparative study, apoptosis induction in human lymphoma and leukemia cell lines was 
assessed using dendrosomes carrying wild type p53(Dend+p53) along with other very 
commonly used non-viral carrier lipofectin (Lipo+p53). The rate of apoptosis in Dend+p53 
transfected K562 cells (human erythroleukemia cell line) which do not produce the p53 protein 
(Buttgereit et al., 2001) was twice that of the Lipo+p53 transfected cells, which was indicative 
of higher transfection efficiency of dendrosomes. In toxicity assessment studies, lipofectin 
showed a higher cytotoxicity on CCRF and MOIT-4 cells (belonging to T-lymphocyte cell lines) 
compared to the dendrosomes used (Massumi et al., 2005). Another study reported successful 
and efficient transfection of A549 (a human lung cell line) by dendrosomes containing the 
recombinant rotavirus VP2 gene equal to that of lipofectin results where dendrosomes showed 
a lower cytotoxicity (Pourasgari et al., 2007). In our recently published work, dendrosomes 
prepared at the IBB center, Iran, were studied and assessed in several aspects including 
interaction of dendrosomes with plasmid and genomic DNA, their ability in delivery and 
expression of genes into Huh7, VERO, Bowes, Raw, U-937, CCRF-CEM, MOLT-4 and K562 
cells, comparison of their performance with a commercial gene porter lipofectin and bacterial 
ghosts, their non-toxicity against human cells and animal models and their performance as 
adjuvant in immunization of BALB/c mice against hepatitis C (Sadeghizadeh et al., 2008). 
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CD spectra of the studied dendrosomes entrapping DNA molecules indicated that the 
commonly used Den123 (made of amphipatic monomers) would moderately cause a 
transition from B- to A-form in linear DNA. Also, sensitivity of the interaction with the GC-
content of DNA was assessed according to the CD spectra information. Results showed that 
dendrosomes generally and mildly transform high and low GC-content DNA from B-form 
into another B-form DNA. Transfection and expression studies also demonstrated that all 
the dendrosomes used could perform best at very low levels and at weight ratios of 
Den/DNA ranging from 1/1 to 1/10 therefore minimizing the chance of undesired side 
effects on the host (Holter & Fordis, 1989). Superiority of Den55 and Den10 compared to 
lipofectin and bacterial ghosts was also seen in these studies. Results from non-toxicity and 
immunization experiments also demonstrated that cells exposed to dendrosomes did not 
show any signs of toxicity whereas those exposed to lipofectin revealed sever toxicity and 
that animal immunization with dendrosomes caused long term immunization of mice 
treated with Den123 carrying the HBsAg or the HCV core pcDNA3 without developing 
signs of toxicity or discomfort (Sadeghizadeh et al., 2008). 
Recently, based on the mentioned desired properties of dendrosomes, our group has 
employed this system for the delivery of a hydrophobic anticancer agent, curcumin into 
tumor cell lines (manuscript in preparation). This new formulation of curcumin, hereafter 
referred to as dendrosomal curcumin, is prepared in a very simple mixing-sonication step, 
and has been shown to significantly improve curcumin water solubility, an important 
limiting factor for the use of free curcumin as a chemotherapeutic. Using the  intrinsic 
fluorescence property of curcumin (Bisht et al., 2007)  and by fluorescence microscopy, 
cellular uptake levels of dendrosomal curcumin were shown to increase significantly 
compared to that of free curcumin, More importantly, using FACS analysis and MTT assays, 
it was demonstrated that as a result of the treatment of human gastric adenocarcinoma cell 
line, with dendrosomal curcumin, free curcumin or void dendrosomes in vitro, the rate of 
apoptosis and cell cycle arrest induced by dendrsomal curcumin was significantly higher 
than that of free curcumin and that treatment of void dendrosomes induced no sign of 
toxicity on the cells. Similarly, administration of dendrosomal curcumin into tumor-bearing 
mice in vivo, abolished tumor progression and toxicological analysis indicated that this 
novel formulation of curcumin did not cause any severe side effects or cytotoxicity in mice.  
Following in vitro assays, our group performed experiments to confirm apoptosis induction 
and tissue uptake of dendrosomal curcumin in vivo. To this end, we injected cancerous cell 
line WEHI-146 (fibrosarcoma) intraperitoneally into BALB-c mice which led to generation of 
tumors in mice. Administration of dendrosomal curcumin into the mice gave rise to 
decrease of size or elimination of tumors. The results of FACS analysis, performed to 
determine the type of cell death, exhibited the occurrence of apoptosis. In comparison with 
negative control samples (void dendrosome and curcumin), the results of  real-time PCR on 
genes underlying apoptosis (both apoptosis stimulatory and inhibitory genes) confirmed the 
induction of apoptosis (manuscript in preparation).  
All together, our data suggest that dendrosomes are not only promising gene carriers, but 
also could be used as efficient drug delivery vehicles for hydrophobic agents.  
4.3 Bacteriophages 
Bactreiophages, also abbreviated as phages, are amongst non-viral biological agents 
employed for gene delivery. Bacteriophages are the most abundant life forms in the 
biosphere and exist in various environments as part of a complex microbial ecosystem 
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(Clokie et al., 2011). These particles are consisting of a DNA or RNA genome contained 
within a protein coat. They infect bacteria and either incorporate viral DNA into the host 
genome, replicating as part of the host (lysogenic cycle), or multiply inside the host cell 
before releasing phage particles by budding from the membrane or actively lysing the cell 
(lytic cycle). 
They could be found almost in all environments even in the human or animal body. The 
normal host of routinely used phages as gene delivery vectors (M13 and lambda) is the well 
characterized bacterium E. coli which is a vital component of the intestinal flora. Therefore it 
could be suggested that at least some bacteriophage species are stable in the gastro-intestinal 
tract and should be transferred intact via lymph into blood circulation. If so, this would raise 
the possibility that phages containing therapeutic genes could be administered orally.  
Although still in the early research stages, bacteriophage vectors offer an attractive 
alternative to various viral and non-viral vectors, because they can potentially overcome the 
drawbacks of either approach (Table 1). For example, a major advantage of bacteriophages 
over animal viral vectors is their lack of natural tropism for animal cells, a major concern for 
current animal viral-vector targeting. Even if non-specific internalization of phage were to 
occur, the production of phage proteins or replicative phages is unlikely in the foreign 
milieu of an animal cell (Larocca & Baird, 2001). 
 
 Animal Virus Synthetic Vector Phage 
Potential toxicity High Low Low 
Generation of competent virus Yes No No 
Viral protein expressed Yes No No 
Complexity High Low Low 
Cost High Low Low 
Gene transfer efficiency High Low Low 
Reproducibility High Low High 
Genetic targeting Limited Limited Yes 
Directed evolution No Yes Yes 
Table 1. A comparison of features of phage vectors with animal and synthetic vectors 
(Larocca & Baird, 2001). 
Also they  possess some other advantages. These include the presence of a capsidic structure 
surrounding the DNA. This is absent in non-viral systems, whose DNA is therefore sensitive 
to degradation, which impairs gene transfer efficacy, especially in gene therapy experiments 
performed in vivo (Schmidt-Wolf & Schmidt-Wolf, 2003 ). The genetic or structural 
modification of capsid proteins can be easily achieved in phages, allowing selective 
targeting of eukaroytic receptors and consequent tissue-specific transduction. Furthermore, 
bacteriophage DNA does not contain eukaryotic sequences and it can be completely 
replaced by exogenous sequences. These characteristics avoid recombination phenomena, 
which have contributed to the doubts raised regarding the clinical safety of eukaryotic 
viruses-derived vectors (Thomas et al., 2003). Phage vector production is expected to be 
simpler and more cost effective than many existing vectors, because phage can be produced 
to high titer in the supernatant of bacterial cultures and easily purified at a large scale. The 
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baceteriophage has generous packaging capacity beyond what most viral vectors like 
adenoviruses (8 kb), adeno-associated viruses (4.7 kb), or lentiviruses (8–10 kb) offer 
(Chauthaiwale et al., 1992). In addition, phages have been experimentally administered to 
animals and safely used in humans for applications that include the treatment of bacterial 
infections (Stone, 2002 ). 
The greatest limitation of phage-mediated gene delivery which has restricted its use is low 
efficiency compared with typical viral vectors. To partially address this problem, one great 
technological achievement called phage display is utilized. Phage display is based on 
expressing recombinant proteins or peptides fused to phage coat proteins. The genetic 
information encoding for the displayed molecule is physically linked to its product via the 
displaying particle.  
Since a major issue in gene therapy is the development of effective vehicles to deliver a 
therapeutic gene to specific target cells to achieve adequate and sustained selective 
expression in the diseased tissue, with minimal toxicity in other tissues, many attempts have 
been prompted in which, by using phage display, natural ligands for cell-surface receptors 
have been linked to phages to enhance the efficiency and selectivity of gene transduction. In 
1999, Larocca et al  first described the transduction of a mammalian cell by a genetically 
targeted filamentous bacteriophage. They modified the phage genome to display fibroblast 
growth factor on its surface coat as an N-terminal fusion to the minor coat protein pIII, and 
showed that such phages undergo receptor-mediated endocytosis, resulting in the 
expression of phage-encoded genes in mammalian cells. 
One of appealing characteristics of phage display is to identify novel cell-targeting ligands, 
which increase the rate and specificity for the transport of macromolecules. Phage-display 
technology offers large collections of potential ligands including short peptides, antibody 
fragments and randomly modified  physiological ligands able to bind to cell receptors. Thus, 
novel ligands can be selected from phage libraries by their ability to deliver a reporter gene 
to targeted cells. With the incorporation of targeting ligands, specificity, delivery and 
efficiency of cell transduction can be dramatically improved. For example, the specificity of 
EGF (epidermal growth factor) -targeted phages is expected to be limited to cells expressing 
EGF receptor, which is elevated in many tumors. 
Previous studies have demonstrated targeted gene-delivery to mammalian cells using 
modified phage-display vectors. Specificity is determined by the choice of the genetically 
displayed targeting ligand. Without targeting, phage particles have virtually no tropism for 
mammalian cells. This raises the possibility of developing phage vectors for targeted gene 
therapy. 
5. Concluding remarks and future perspectives 
It is well established that the key to gene therapy research is development of proper gene 
carriers. Calcium-phosphate precipitation, use of DEAE, PEIs, PLLs, polybrene/dimethyl 
sulfoxide, liposomes, cationic amino polymers and dendrimers are major chemical methods 
used for transfection of genes. However, only liposomes and dendrimers are widely used 
for efficient in vivo gene delivery and the other methods usually have a lower efficiency and 
can be applied only in vitro. Lipsomes and dendrimers also have limitations such as fast 
clearance of liposomes from blood, degradation of their content by lysosomic enzymes as 
they are phagocytosized, hemolytic toxicity and cytotoxicity of dendrimers owing to their 
cationic nature and premature release of the dendrimer’s cargo in plasma.  
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Dendrosomes, however, might be an exception in this regard. Dendrosomes are non-viral 
nanovehicles that form stable, biodegradable, neutral, readily synthesized hyperbranched 
spherical nanostructurs. They not only can deliver genes of various sizes and drugs into 
target cells but also have been proven to be efficient porters for DNA vaccination in vivo. A 
unique feature of dendrosomes is the ease with which they provide suitable inert gene 
porters for various DNA sizes and target cells. Dendrosomes may trap DNA molecules 
within their arms or/and form clusters entrapping DNA inside with no strong electrostatic 
bonds, but rather with weak interactions with DNA. This is important as most DNA carriers 
make bonds with DNA and condense it to a proper size for carriage and this reduces the 
expression of the condensed DNA even when successfully transfected into cells. But, 
dendrosomes do not condense DNA while entrapping it efficiently enough for transfection 
both in vitro and in vivo with no toxicity on target cells. However, optimizing the 
DNA/dendrosome ratio and safe amounts of the carrier is an essential step to be 
considered.  
Bacteriopahges present tantalizing opportunities for therapeutic applications given further 
research and development. Exploiting the natural properties of these biological entities for 
specific gene delivery applications will also expand the repertoire of gene therapy vectors 
available for clinical uses. The discovery that targeted displayed phage can deliver genes to 
cells has created new opportunities for expanding the use of phage-display in gene 
discovery and now gene therapy. 
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